Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down Syndrome and Normal Aging

Pre-clinical study with recombinant murine GM-CSF reversed cognitive impairment in Dp16 model of Down syndrome and improved cognitive function in aged normal mice

The CU Anschutz Medical Campus team recently awarded a grant from the National Institutes of Health/National Institute on Aging to study Leukine® treatment in young adults with Down syndrome

Lexington, MA – March 29, 2022 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of results from investigator-sponsored pre-clinical research evaluating use of ...

Continue Reading →